TAXIS PHARMACEUTICALS, INC.
Novel antimicrobial resistance therapies targeting the molecular basis of bacterial resistance
- Sector
- Biotech
- Headquarters
- MONMOUTH JUNCTION, NJ
- Founded
- 2009
- Latest Form D
- $1.1M, Jan 2019
- Total capital
- $9.4M
- Federal grants
- $3.8M
- 4 awards · 2024–2026
- Rank in peer group#167 of 514
- Private capital raised
- $5.6M
- 5 Form D · last Jan 2019
- 94 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 6
- 34 pending · first 2016
- Rank in peer group#58 of 514
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Lead optimization of oral DHFR inhibitor for the treatment of multidrug-resistant N. gonorrhoeae infections.$1M
- Federal grantHealth and Human S · Phase II · Lead optimization of oral DHFR inhibitor for the treatment of multidrug-resistant N. gonorrhoeae infections.$1M
- Federal grantHealth and Human S · Phase II · Lead optimization of a novel cyclic aryl-indole efflux pump inhibitor (EPI) series in combination with levofloxacin against Pseudomonas aeruginosa$890K
- Federal grantHealth and Human S · Phase II · Lead optimization of a novel cyclic aryl-indole efflux pump inhibitor (EPI) series in combination with levofloxacin against Pseudomonas aeruginosa$910K
- Private capital raisedForm D · SEC · 5th filing$1.1M
- Offering registeredForm D · SEC · 4th filing$5M
- Private capital raisedForm D · SEC · 3rd filing$1.2M
- Private capital raisedForm D · SEC · 2nd filing$3M
- Private capital raisedForm D · SEC · 1st filing$237K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#167 · top 32%
- Granted patents#58 · top 11%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Edmond LaVoieResearcherDirectorLinked by 2 patents
- Christopher M. CimarustiDirectorNamed in SEC Form D filings
- Daniel S. PilchDirectorNamed in SEC Form D filings
- David G. KimballDirectorNamed in SEC Form D filings
- Ernest S. MarioDirectorNamed in SEC Form D filings
- Gail McIntyreDirectorNamed in SEC Form D filings
Show all 8 people
- Greg MarioExecutive Officer, DirectorNamed in SEC Form D filings
- Gregory G. MarioExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 6 granted of 40- PendingSynthetic Processes And Synthetic IntermediatesUSPTOApplication 18958741
- PendingAntibacterial AgentsUSPTOApplication 19037815
- GrantedSynthetic Processes And Synthetic IntermediatesUSPTOUS 12,173,013
Show all 40 patent records
- Synthetic Processes And Synthetic IntermediatesAug 14, 2025 · Application 18958741Pending
- Antibacterial AgentsJun 5, 2025 · Application 19037815Pending
- Synthetic Processes And Synthetic IntermediatesDec 24, 2024 · US 12,173,013Granted
- Therapeutic CompoundsSep 26, 2024 · Application 18572411Pending
- Bacterial Efflux Pump InhibitorsJul 18, 2024 · Application 17927645Pending
- Therapeutic Compounds And Methods To Treat InfectionDec 19, 2023 · US 11,845,742Granted
- Antimicrobial AgentsSep 28, 2021 · US 11,129,814Granted
- Synthetic Processes And Synthetic IntermediatesMay 13, 2021 · Application 16997716Pending
- Synthetic Processes And Synthetic IntermediatesSep 15, 2020 · US 10,774,093Granted
- Therapeutic Compounds And Methods To Treat InfectionJan 31, 2019 · Application 16046696Pending
- Antimicrobial AgentsSep 11, 2018 · US 10,071,082Granted
- Antimicrobial AgentsJun 28, 2018 · Application 15668506Pending
- Compounds For The Treatment Of Bacterial InfectionsOct 26, 2017 · Application 15313046Pending
- Antimicrobial AgentsOct 4, 2016 · US 9,458,150Granted
- Antimicrobial AgentsOct 29, 2015 · Application 14705770Pending
- Therapeutic Methods To Treat InfectionApplication 62586003Pending
- Therapeutic Methods To Treat InfectionApplication 62538547Pending
- Therapeutic Methods To Treat InfectionApplication 62525079Pending
- Bacterial Efflux Pump InhibitorsApplication 62523154Pending
- Bacterial Efflux Pump InhibitorsApplication 62523156Pending
- Bacterial Efflux Pump InhibitorsApplication 62511851Pending
- Bacterial Efflux Pump InhibitorsApplication 62470009Pending
- Bacterial Efflux Pump InhibitorsApplication 62469987Pending
- Bacterial Efflux Pump InhibitorsApplication 62470038Pending
- Synthetic Processes And IntermediatesApplication PCTUS2017019161Pending
- Bacterial Efflux Pump InhibitorsApplication PCTUS2017019198Pending
- Antimicrobial AgentsApplication 15406217Pending
- Bacterial Efflux Pump InhibitorsApplication 62299450Pending
- Compounds For The Treatment Of Bacterial InfectionsApplication PCTUS2015032052Pending
- Antimicrobial AgentsApplication PCTUS2013069316Pending
- Bacterial Efflux Pump InhibitorsApplication 19513381Pending
- Bacterial Efflux Pump InhibitorsApplication PCTUS2024043485Pending
- Antibacterial AgentsApplication 18674256Pending
- Antibacterial AgentsApplication 18377998Pending
- Bacterial Efflux Pump InhibitorsApplication 63534262Pending
- Antibacterial AgentsApplication 18107206Pending
- Therapeutic CompoundsApplication PCTUS2022034374Pending
- Therapeutic CompoundsApplication 63213519Pending
- Bacterial Efflux Pump InhibitorsApplication PCTUS2021034963Pending
- Bacterial Efflux Pump InhibitorsApplication 63032160Pending
Related companies, and why
- Pattern Pharma Inc.Similar federal contract value in Biotech · null in contracts
- Pretzel TherapeuticsSimilar federal contract value in Biotech · null in contracts
- COMPANION SCIENCES, INC.Similar federal contract value in Biotech · null in contracts
- Phi Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- GENERAL BIOPHYSICS, LLCSimilar federal contract value in Biotech · null in contracts
- DiaMedica Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .